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Summary
Exploitation of embryonic stem cells (ESC) for therapeutic
use and biomedical applications is severely hampered by the
risk of teratocarcinoma formation. Here, we performed a
screen of selected epi-modulating compounds and
demonstrate that a transient exposure of mouse ESC to
MS-275 (Entinostat), a class I histone deacetylase inhibitor
(HDAC), modulates differentiation and prevents
teratocarcinoma formation. Morphological and molecular
data indicate that MS-275-primed ESCs are committed
towards neural differentiation, which is supported by
transcriptome analyses. Interestingly, in vitro withdrawal of
MS-275 reverses the primed cells to the pluripotent state. In
vivo, MS275-primed ES cells injected into recipient mice give
only rise to benign teratomas but not teratocarcinomas with
prevalence of neural-derived structures. In agreement, MS-
275-primed ESC are unable to colonize blastocysts. These
findings provide evidence that a transient alteration of
acetylation alters the ESC fate.
 2013. Published by The Company of Biologists Ltd. This
is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distributin and reproduction in any
medium provided that the original work is properly
attributed.
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Introduction
Epigenetic regulation refers to the modulation of gene expression
in cellular heritability, fate, development and (re)programming
other than through alterations of the DNA sequence itself (Kim
et al., 2010; Orkin and Hochedlinger, 2011). Aberrant epigenetic
regulation has been directly linked to human diseases such as
cancer (Martens et al., 2010) and epigenetic modulating
compounds, the so-called ‘epidrugs’, have entered into the
clinic (Manzo et al., 2009). A plethora of studies have revealed
that in embryonic stem cells (ESCs) the structure of chromatin
influences the expression of the pluripotency genes and
characteristics, such as the transcription factors (TFs) Oct4 and
Nanog (Chambers et al., 2003; Loh et al., 2006; Niwa et al.,
2000). The relationship between TFs and chromatin organization
is essential for both stem cell potential and differentiation (Arney
and Fisher, 2004; Atkinson and Armstrong, 2008; Bernstein et al.,
2006; Dovey et al., 2010; Golob et al., 2008; Karantzali et al.,
2008; Orkin and Hochedlinger, 2011). Although the involvement
of epigenetic mechanisms in self-renewal, pluripotency and
regulation of differentiation has been extensively investigated
(Atkinson and Armstrong, 2008), we are far from understanding
phenomena such as the metastability of ESCs (Hayashi et al.,
2008) and the heterogeneity of ESC-derived differentiated cells
(Mummery et al., 1990). The concept that during embryo
development the major epigenetic changes affecting genome
regulation represents the conversion from a euchromatic to a
heterochromatic compact state (Arney and Fisher, 2004) has been
amply debated (Golob et al., 2008; Marks et al., 2012). As ESCs
have the intrinsic ability to give rise to all differentiated tissues
(Boiani and Scho¨ler, 2005; Chambers and Smith, 2004; Golob
et al., 2008; Marks et al., 2012; Solter, 2006), they represent a
powerful model to decrypt both the mechanism(s) of pluripotency
and the potential impact of epigenetic modulators on stem cell
and differentiation potential (Arney and Fisher, 2004; Dovey
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et al., 2010; Hsieh et al., 2004; Karantzali et al., 2008; Kim et al.,
2010; Lee et al., 2009; Lenka and Ramasamy, 2007). In this
scenario, it is not unexpected that epidrugs act as modulators of
stem cell potentiality and/or differentiation of ESCs. Indeed, the
histone deacetylase inhibitor (HDACi) VPA (Valproic Acid) has
been reported to impact on differentiation (Jergil et al., 2011; Lee
et al., 2009) and the G9 methyl-transferase inhibitor, BIX01294,
to affect reprogramming (Medvedev et al., 2011).
Here, we identify MS-275 (MS-275) a class I histone
deacetylase inhibitor (HDAC) as a modulator of the
differentiation potential of ESCs. We identified MS-275 in a
cell-based screen as a regulator of mouse ESC proliferation and
priming into differentiation. Notwithstanding, MS-275-induced
ESC priming is fully reversible in vitro. MS-275-primed ESCs
only give rise in vivo to benign teratomas, but not
teratocarcinomas, with prevalence for neural-derived structures.
Moreover, ESCs transiently treated with MS-275 were unable to
colonize blastocysts. We thus suggest that the higher acetylation-
state primes ESCs into neural-bound commitment.
Results
ESC proliferation is affected by chromatin modifying drugs
To investigate the impact of epigenetic modulators on ESC growth,
we screened a small selection of known epidrugs targeting diverse
classes of chromatin enzymes using an integrated robotic
workstation (Casalino et al., 2011). EGFP-marked mouse ESCs
(b-actin EGFP-TBV2) were plated in feeder-free gelatin-coated 96-
well plates and allowed to adhere for 6 hours before the addition of
selected epidrugs at four different concentrations (supplementary
material Table S1). Following 36 hours of culturing in the presence
of the compound, EGFP-derived fluorescence was quantified as a
proxy of cell proliferation. A subset of the results is represented as a
heat map (Fig. 1A). All-Trans Retinoic Acid (ATRA), included as a
positive control, showed the expected pro-proliferative effect as
compared to the control (vehicle) (Fig. 1A). HDACis, such as
Vorinostat (SAHA) (Butler et al., 2000) (Fig. 1B) and MS-275 (MS-
275) (Park et al., 2004; Saito et al., 1999) (Fig. 1C), displayed a
dose-dependent effect, being cytotoxic at higher doses and pro-
proliferative at lower concentrations (supplementary material Table
S1). A similar effect was obtained with BIX01294, a G9
methyltransferase inhibitor (HMTi) (Chang et al., 2009) (Fig. 1D).
Validation by cell count confirmed these results (supplementary
material Fig. S1A) and both SAHA and MS-275 displayed dose-
dependent HDAC1 inhibition (supplementary material Fig. S1B).
Treatment of ESCs (or b-actin EGFP-TBV2 cells) with SAHA
or MS-275 for 12 h and 24 h strongly increased acetylation of
H3K9 (Fig. 2A), H3K18 and H3K23 (supplementary material
Fig. S2A,B). Interestingly, a physiological increase of H3K9
acetylation, i.e. in absence of any ‘epidrug’ treatment, was also
observed during neural and cardiac differentiation (Fig. 2B),
suggesting that increased acetylation might impact on ESC
differentiation potential.
Transient MS-275 treatment promotes neural differentiation of
ESCs in vitro
To evaluate the ability of acetylation to modulate ESC
differentiation in vitro, TBV2 cells were pre-treated for 24 hours
with MS-275 (5.0 mM) or DMSO (0.1%) as control vehicle, and
then induced to neuronal differentiation, as previously described
(Fico et al., 2008) (Fig. 3A–C). At day 8 of differentiation, Nestin-
positive rosette-like clusters, typical of neural precursor, were
much more expanded in ESC MS-275-pulsed -derived progeny
compared to control. Although the beta-III-tubulin-positive mature
neurons with complex neurite branching or outgrowth were clearly
detectable at day 12 and 18 of differentiation for both solvent and
MS-275-pulsed cells, MS-275-pulsed cells yielded more GFAP-
positive glial cells. RT-qPCR data confirmed the difference
observed in the relative abundance of neural progenitors and glial
cells. The MS-275-pulse caused a slight decrease of the
neuroectodermal marker Pax6 expression, accompanied by an
earlier, and more sustained expression of Nestin (Fig. 3D). Small
differences until the day 12 of differentiation in bIII-tubulin levels
were observed; in contrast at day 18, a higher level after the
treatment is detectable. In addition, the RT-qPCR data confirm and
strengthen the strong increase of GFAP in treated cells, already
observed with immunohistochemistry (Fig. 3C,D).
MS-275 treatment reversibly impacts on stem cell potentiality
in vitro
The fact that the H3K9ac level induced by the HDACis MS-275
or SAHA is reminiscent of the strong increase of H3K9ac
observed during ESC differentiation (Fig. 2B) and that MS-275
treatment impacts on neural differentiation (Fig. 3A–C)
prompted us to investigate whether the epidrug-treated ESCs
still display a pluripotent status using the alkaline-phosphatase
(AP) colony formation assays (O’Connor et al., 2008) (Fig. 4A).
With this aim, TBV2 cells pretreated for 24 hours with the three
selected epidrugs (SAHA, MS-275, BIX01294) were plated at
low density and the colony morphology was observed at day 4
after plating. Based on both AP staining and colony morphology,
the colonies were classified into 3 main categories: i)
undifferentiated colonies with well defined, rounded shape and
strong AP staining; ii) colonies with low AP staining retaining
Fig. 1. Effects of different drugs on ESC proliferation. (A) Mouse
embryonic stem cells (TBV2) engineered for the expression of Enhanced Green
Fluorescent Protein under the control of beta actin promoter (b-actin/EGFP
TBV2) were plated in automation by using the Cellmaker and treated with the
indicated drugs after 6 h. The fluorescence emitted was recorded after 42 h.
The data were validated by semi-automated counts for MS-275, BIX01294
(supplementary material Fig. S1A). The columns are increasing concentrations
of the compounds. The list of drugs and concentration is shown in
supplementary material Table S1. (B–D) The structures of SAHA, MS-275, and
BIX-01294, respectively.
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defined edges and rounded features and iii) AP negative colonies
showing a flat morphology. While, as expected, almost 100% of
the control colonies displayed a characteristic round-shape
morphology, nearly 40% of the colonies showed a flat
phenotype with irregular edges and loss of AP staining after
treatment with 5.0 mM MS-275 (third lane, Fig. 4A).
Immunofluorescence analysis showed reduced expression of the
pluripotency markers OCT4 and SSEA-1 in ESCs treated with
MS-275 5.0 mM compared to the control (Fig. 4B), thus
corroborating the potential decrease of stem cell potential
despite the presence of LIF in the culture medium. Taken
together, these findings showed that pre-treatment with MS-275
causes loss of pluripotency features and primed ESCs for
differentiation. Interestingly, when MS-275 was transiently
applied for 24 hrs and then washed out and cells re-plated and
propagated for 4 passages (p1–p4) (Fig. 5A) with medium change
every two days, by passage 4 MS-275-treated cultures regained the
morphological (clonogenicity and colony shape) and molecular
(expression of the ESC-associated genes Oct3/4 and Lefty1 and
downregulation of differentiation markers SOX17 and Brachyury)
features of ESCs (Fig. 5A–D), thus suggesting that MS-275-
induced biological effect was fully reversible. In full agreement,
modulation occurring at H3K9Ac post MS-275 treatment (Fig. 5E)
and ESC proliferation were also reversible. Similar results were
obtained using MS-275 at 0.5 mM (supplementary material Fig.
S3). All together our findings support the hypothesis that MS-275-
induced hyperacetylation impacts on ESC pluripotency potential
and point to a fully reversible effect of this epidrug.
Expression analysis of MS-275-primed ESCs reveals
commitment to neural differentiation
Transient MS-275 modulation of stem cell and differentiation
markers (Fig. 5) prompted us to apply a Differential in Gel
Electrophoresis (DiGE) followed by ‘‘In Situ Digestion’’ and
nano LC-MS/MS interpretation (Mascot search engine) to
determine protein targets. Almost 200 proteins were identified
with differential expression after 5.0 mM MS-275 (only mild
Fig. 2. Histone acetylation upon chromatin modulator treatment and
during ESC differentiation. (A) Western blot for H3K9 acetylation: lanes 1,2:
DMSO; lanes 3,4: MS-275 at 5.0 mM; lanes 5,6: MS-275 0.5 mM; lanes 7,8:
SAHA at 5.0 mM; lanes 9,10: SAHA at 0.5 mM; lanes 11,12: BIX-01294 at
1.0 mM; lanes 13,14: BIX-01294 at 0.1 mM. Odd and even numbers are at 12 h
and 24 h, respectively. (B) Acetylation levels of H3K9 during neural and
cardiac differentiation: lane 1) undifferentiated stem cell; lanes 2–4, neuronal
differentiation at 4, 8 and 10 days, respectively. Lanes 5–8: at 4, 8 and 10 and
13 days. The H4pan antibody recognizes K 4-7-11-15ac. Histone H4 and
Ponceau Red are used as loading controls. Asterisk represents the molecular
weight marker.
Fig. 3. MS-275 impacts on neural differentiation of ESCs in vitro. ESCs
were pretreated for 24 hours with solvent (DMSO 0.1%) or 5 mM MS-275 and
then re-plated for neural differentiation. (A–C) Immunostaining at 8, 12 and 18
day post plating (dpp) of ESC neuronal differentiation, respectively. Cells were
fixed and stained with antibodies specific for Nestin, bIII-tubulin and GFAP,
showing the presence of neural progenitors, mature neurons and glial cells,
respectively. Nuclei were counterstained with Hoechst. Phase contrast (PC) and
overlay fluorescence picture are shown. Scale bars: 400 mm. (D) RT-qPCR
analysis of neural markers: neuro-ectoderm (Pax6) neural progenitors (Nestin),
mature neurons (bIII-tubulin) and Glia (GFAP). mRNA was normalized to
GAPDH. Data are means of three independent experiments (error bars: 6
S.D.). *p,0.001.
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fluctuations with the lower MS-275 concentration, supplementary
material Figs S4, S5). GO analyses indicated modulation of
differentiation and neural-oriented pathways (supplementary
material Fig. S5; Table S2), yet, the previously identified
markers (Fig. 5A–D), were not among them. To further
investigate differential expression, two replicas of genome-wide
transcriptome profiles (RNA-seq) were generated from cells
treated for 24 hours with vehicle or MS-275 at 5 mM in presence
of LIF. The data (GEO GSE45909) were analysed using the
Genomatix tool and normalized expression values were com-
pared between vehicle and treated at 0.5 mM and 5.0 mM. 1822
genes had higher expression values in the MS-275 treatment at
5.0 mM, whereas only 245 genes were downregulated. The
treatment with 0.5 mM MS-275 yielded to 46 up- and 66
downregulated. Venn diagram shows the overlap of up- and
downregulated genes between the two conditions (Fig. 6A).
Moreover, David tool (http://david.abcc.ncifcrf.gov) was used for
GO enriched terms; results are shown (Fig. 6B,C). Within the
most enriched terms were ectoderm and neurogenesis and
included neural lineage precursor genes such as Nestin, Hey1
and 2, Foxn4, Id2 and 4. Clearly, 5.0 mM MS-275 induced loss of
pluripotency markers (Fig. 5) and enhanced expression of
differentiation-related genes, in particular in ectoderm and neural
differentiation (Fig. 6). Interestingly, Fgf1, Lefty1 SOX17 and
Brachyury were modulated as previously found (Fig. 5), thus
corroborating and extending the evidences that MS-275 primes
ESC versus neural differentiation. The small number of up- and
downregulated genes in the treatment condition of 0.5 mM did not
allow a statistically sound interpretation. Given that Epiblast Stem
Cells (EpiSCs) have been described as ESC with a specific
transcriptome and incapacity to colonize blastocysts (Bernemann
et al., 2011), we also compared the expression profile of TBV2 cells
(with and without MS-275) to the Epi-SC profile using
MultiExperiment Viewer (http://www.tm4.org/mev.html) (Fig. 6D).
The pairwise comparison of non negative matrix factorization based
Spearman rank correlation demonstrated that MS-275 treated ES cells
are more closely related to untreated ESC that to EpiSC.
Transient MS-275-treatment impacts on ESC-derived teratoma
formation and composition in vivo
When introduced into immunodeficient mice, ESCs
spontaneously form teratoma-like masses, containing ectoderm-
derived (such as nerve and skin), mesoderm-derived (bone,
blood, and muscle) and endoderm-derived (gut) tissues (Thomson
et al., 1998). As the formation of differentiated tissues from
all the three somatic germ layers in the teratomas is taken as
one of the pluripotency indicators characteristic for ESCs
(Lensch et al., 2007), we tested the teratoma-forming ability of
Fig. 5. Reversible effect of MS-275 on ESCs. (A) Schematic representation of
the experiment: T 5 treatment of 24 h with 5.0 mM MS-275; p1–p4: days of
medium change and photo collection. (B) Photo in bright field of solvent and
drug treatment at p1, p4. (C) q-PCR of solvent and MS-275 at 5.0 mM
concentration treated cells at p1 and p4 for the indicated markers; *p,0.01.
(D) Colony formation assay for each day and treatment. (E) H3K9 Acetylation
(Ac) levels after 24 h of treatment with MS-275 at 5.0 mM and at the different
passages (p1, p2, p3 and p4). Scale bars: 200 mm (B), 400 mm (D).
Fig. 4. HDAC inhibitors modulate ESC stem cell potential at
morphological and molecular level. (A) Effect induced by the indicated
compounds on ESC colony morphology and alkaline phosphatase staining.
(B) Immunofluorescence of ESC stained for DAPI-OCT4-SSEA-1. Upper
panel: control; lower panel: MS-275 at 5.0 mM for 24 h.
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the MS-275-treated ESCs. ESCs were exposed to MS-275
(5.0 mM) for 24 h, or to vehicle as control, and injected
subcutaneously into the flanks of SCID mice. Given the
different growth kinetics, animals were sacrificed at different
times (Fig. 7A) depending on the tumor dimension. Due to
reduced tumor dimension, some animals were sacrificed after 22
days from cells injection. The histopathological analysis showed
that control tumours displayed different degrees of differentiation
and tissues types (Fig. 7C1–4), as well as three-dimensional
teratocarcinoma formation (Fig. 7C3–6). Importantly, in vitro
MS-275 pretreated cells failed to form teratocarcinomas
developing only well-differentiated teratomas, with a
prevalence of epithelial and neural tissues, such as small
neuronal tubes (Fig. 7C8,9) and absence of respiratory
epithelium, cartilage and smooth muscle, compared to control.
Histo-pathological conclusions are summarized in Fig. 7B.
Taken together these data suggest that MS-275-pretreated
ESCs, despite retaining the ability of teratomas formation with
a preponderance of neural lineage-specific tissues
(neuroectodermal structures), had lost the potential of forming
malignant teratocarcinomas.
Dose-dependent effect of in vitro MS-275 treatment on ESC
contribution to embryo development
Given that pre-treatment with MS-275 reduced the pluripotency
potential of ESCs in vitro, which maintain the ability to generate
teratomas in vivo, we questioned whether their contribution to
embryo formation might be compromised. To this end, EGFP-
TBV cells were pretreated in vitro with 0.5 and 5.0 mM MS-275
for 24 hours, or with vehicle as control. After washout of solvent
and MS-275, cells were injected in about 30 blastocysts and
transferred to the uterus of pseudo-pregnant female recipient CD-
1 mice. Interruption of mice pregnancy at day 11 (E11) post-
coı¨tum (d.p.c.) was performed, embryos were dissected and
images captured using a fluorescence stereomicroscope. While
cells pretreated in vitro with solvent and 0.5 mM MS-275 (data
not shown) still contributed to the entire embryo, in vitro pre-
treatment with 5.0 mM MS-275 showed absence of EGFP signal
in the embryo (Fig. 7D,E; supplementary material Table S3).
This observation corroborates and extends our conclusion that in
vitro transient exposure to 5.0 mM MS-275 affected pluripotency
and/or ESC differentiation potential in vivo, thus affecting final
tissue formation.
Discussion
The effects of chromatin modulators (epidrugs) on stem cell
potentiality and differentiation have been poorly addressed. This
topic is, however, of particular relevance given that epidrugs are
entering the clinics and their potential action on adult stem cells
might influence both treatments and time of patient’s recovery.
Moreover, a bottleneck of the use of embryonic stem cells in
therapy is the risk of teratocarcinoma formation, thus suggesting
that tools aiming at prevention of formation of ESC-derived
tumors might increase their therapeutic applications.
The notion that the differentiation potential of pluripotent
embryonic stem cells (ESCs) is highly affected by their
epigenetic status together with the availability of several epi-
enzyme modulators (epidrugs) led us to hypothesize that epidrugs
might be useful tools to modulate ESC differentiation.
Supporting this hypothesis, recent studies suggest that
Vorinostat, BIX-01294 and Tricostatin A (TSA) may play a
role in the ESC differentiation (Milde et al., 2011; Shi et al.,
2008). Here we show that the acetylation levels of H3K9ac
(Fig. 2A) as well as for H3K23ac and H3K18ac (Wang et al.,
2008), specifically increase during key steps of ESC
differentiation and that treatment of ESCs with HDACi such as
MS-275, mirrored this phenomena. We further showed that MS-
275 initially caused an increase followed by a decrease of
proliferation reminiscent of maturation processes. That in this
setting MS-275 behaved similarly to SAHA (Vorinostat) is a
point of particular interest given that i) Vorinostat has been
reported to alter ESC pluripotency (Park et al., 2011) and ii) only
class I HDACs (and mainly HDAC1 and 2) are inhibited by MS-
275, thus restricting the epi-targets potentially responsible for this
effect. Moreover, the concentration dependent dual growth effect
– positive and negative proliferative action displayed by some
epidrugs amongst which MS-275 – correlates the growth
modulation with the enzyme inhibition suggesting target
specificity. Thus, the HDACi treatment seems to recapitulate
the hyper-acetylation state characteristic of specific steps of
differentiation (Fig. 2B) strongly suggesting that HDACi cause
loss of stem cell potential and modulate induction of
differentiation.
Whether the hyper-acetylated state of chromatin occurring
during neural and cardiac differentiation (Fig. 2B) represents
a causal step or an effect of induction of differentiation represents
a crucial point of reflection. Interestingly, in mouse ESCs, a
Fig. 6. Gene expression profiles suggest neural orientation upon MS-275
treatment. (A) Venn diagram of up- and downregulated genes of 0.5 mM and
5.0 mM MS-275 versus solvent, respectively. (B,C) Gene ontology results for
up- and downregulated genes, respectively. (D) Spearman Rank Correlation
between MS-275 5.0 mM treated TBV2 and Epi-SCs.
HDACi MS-275 modulates mESC fate 1074
B
io
lo
g
y
O
p
e
n
hyper-acetylated state is reached both in neural and cardiac
differentiation with different time courses, being clearly visible at
day 8 and 10 in neural and cardiac differentiation, respectively.
Despite the different settings, these observations might be
interpreted in diverse ways. The timing itself may be crucial;
neural differentiation might simply need increased acetylation at
an earlier time point compared to cardiac differentiation.
Alternatively or in addition, hyper-acetylation might be induced
in distinct chromatin areas in the two differentiation programs,
which eventually induce hyper-acetylation of different chromatin
areas. Obviously, both options might co-occur, being both time of
acetylation and areas of acetylation key events to be executed. In
the same time result very interesting the capability of ESCs to
revert phenotype and biochemistry effect due to MS-275
treatment.
In agreement with the hypothesis that HDACi targeting
HDAC1 and 2 might influence differentiation, a transient, one-
day pulse of MS-275 pre-treatment (to a higher extent than
SAHA) altered the colony morphology of ESCs even in the
presence of LIF supporting an active role of MS-275 for
differentiation commitment and highlighting the option that
timing of hyper-acetylation might play a role in pluripotent stem
cell differentiation. In accordance, the treatment of ESCs with
MS-275 (in presence of LIF) primed differentiation
predominantly along neural lineages. Indeed, RNA-Seq analysis
revealed a significant neural-oriented modulation together with a
decrease of embryonic functional genes, suggesting an active
modulation of HDACi vs ESC differentiation as well as
corroborating that temporal frame of hyper-acetylation might
actively prime a neural-oriented fate. Interestingly, teratoma
formation in vivo indicates that pluripotency is largely unaffected
in MS-275-primed ESCs given that teratomas are present in all
animal groups, although HDACi priming caused a preponderance
of differentiated tissues towards a neuronal phenotype. Whether
the preponderance towards neuronal differentiation in vivo is due
to induction of neural differentiation as a consequence of the MS-
275 treatment and/or to the repression of other differentiation
programs remains to be established. Importantly, MS-275
treatment and likely the acetylation status of ESCs at the
moment of the injection altered the cancer potential within
teratomas given that no malignant teratomas were formed. Most
remarkably, MS-275-treated ESCs were unable to contribute to
hybrid embryos similar to Epiblast Stem Cells (EpiSC)
(Bernemann et al., 2011). However, the expression profiles of
treated ESCs are more similar to untreated ESCs than to EpiSC.
In conclusion, given the potential of pluripotent stem cells in
biomedical applications, a better comprehension of the
mechanism(s) of differentiation both in vitro and in vivo and
insights into potential pharmacological approaches to modulate
differentiation may represent the road ahead for personalized
medicine.
Materials and Methods
Cell culture
The feeder-dependent mouse embryonic stem cells TBV2 (129/SvP; wild type or
EGFP-transgenic) have been used throughout the study and maintained in culture
as described previously (Casalino et al., 2011).
Compounds
A collection of compounds was chosen for screening analysis (A´lvarez et al., 2009;
Bieliauskas and Pflum, 2008; Go¨ttlicher et al., 2001; Grozinger et al., 2001; Hu
et al., 2003; Kubicek et al., 2007; Lin et al., 1998; Park et al., 2008; Richon et al.,
1996; Sealy and Chalkley, 1978; Zhang et al., 2009). The majority of compounds
were purchased from Sigma–Aldrich; psammaplin A and UVI5008 were obtained
by Prof. A. de Lera, BMS641 was a kind gift of BMS Pharma, SAHA was a kind
gift of Merck and MS-275 was purchased from Alexis. Diamide was included as
Fig. 7. MS-275 in vitro priming
impacts both on terato-carcinoma
development and content as well as
blastocysts colonization in vivo.
(A) Teratoma growth rate; x-axis: days
of life of each mouse; y-axis: number of
mice alive. (B) Post-surgery analysis of
teratoma composition. (C) Anatomic/
pathologic evaluation. Upper panels:
control (ctr); lower panels: lesions
obtained in teratomas derived from in
vitro 5.0 mM MS-275 pre-treated cells.
1: cartilage and respiratory epithelium;
2: respiratory epithelium and smooth
muscle; 3: neuron tubes; 4:
immunohistochemistry of pan-
cytokeratin, demonstrating the
epithelial origin of the structure; 5,6:
teratocarcinoma tumor histo-
pathological pattern; 7,8: neuron tubes;
9: a mature neuron (see asterisk); 10:
immunohistochemistry for GFAP
showing glia formation; 11,12:
teratoma tumor histopathological
pattern. (D,E) Chimera formation
assay. Representative
photomicrographs (fluorescence/bright
field) of the embryos (E11) obtained
after blastocyst injection with
engineered TBV cell treated with MS-
275 (5.0 mM) (E) and solvent (D).
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negative control. Details are described in supplementary material Table S1. For
mother plate preparation, compounds were diluted in PBS 16. Compounds were
added randomly at 96 multi-wells plates in tripled, excluding external side of plate,
which is filled with PBS 16.
ESC proliferation assay and counting
ESC-EGFP were counted and suspended at 105 cells/mL, from which 104 cells/
well were seeded in 96 gelatin multi-well plates, for a total volume of 100 mL.
Cells were left adhere for 12 hours and then compounds were added. After
36 hours from treatment the cell layer was washed and fluorescence measured with
TECAN Infinite M200.
For cell counting, TBV2 cells were seeded in duplicate at a density of 250,000
cells/well in 6 multi-well plates (this is equivalent at adopted density for the
screening in MW96). Medium culture was changed after 24 hours, and, at
stimulation of 36 hours, cells were removed, diluted in Trypan blue (Sigma) and
counted.
HDAC assay
The assay was performed as described previously (Nebbioso et al., 2011).
Protein extraction, Western blots
Cells were lysed in 200 mL of lysis buffer (Tris–HCl 50 mM, NaCl 150 mM, NaF
10 mM, NP-40 1.0%) with 10 mL/mL of PIC (Sigma–Aldrich) and 200 mM of
PMSF (Sigma–Aldrich). Proteins were quantified using ‘‘Bio-rad protein assay’’.
Histone extraction and Western blots were performed as described previously
(Nebbioso et al., 2009). Antibodies used: H3 pan-Acetyl (UPSTATE 06-599); H4
pan-Acetyl (UPSTATE 06-866); H3K9Ac (AB4441); H3 (AB1791); H4
(AB7311); H3K12ac (AB1191); H3K4me (AB8895); H3K9me (AB9045);
HDAC4 (AB1437); HDAC5 (AB47519); HDAC2 (AB7029); HDAC4-6
(SIGMA H2287); HDAC1 (SC7872); HDAC3 (AB70030); H3K9me (AB9045);
H3K4me2 (AB32356); H3K4me3 (AB8580); H3K9me2 (AB1220); H3K9me3
(AB8898); H3R17me2 (AB32356).
Colony formation assay
Cells were plated at low density (1000 cell/cm2) on gelatin plates in a medium for
undifferentiated ESCs. Compounds were used as indicated. After 5 days cells were
fixed (4% paraformaldehyde in PBS 16) for 2 minutes. Then, cells were washed in
rinse buffer 16 (20 mM TRIS–HCl, pH 7.4, 0.15 M NaCl, 0.05% Tween-20).
Alkaline Phosphatase Detection Kit (Chemicon International) was used for
staining. Cells counted at microscopy as colonies number expressing alkaline
phosphatase.
RNA isolation, reverse transcription, RNAseq and qPCR analysis
The experiments were performed as described previously (Marks et al., 2012).
Briefly total RNA was isolated with Trizol (Invitrogen) and 100 mg total RNA was
subjected to two rounds of poly(A) selection (Oligotex mRNA Mini Kit;
QIAGEN), followed by DNaseI treatment (QIAGEN). 100–200 ng mRNA was
fragmented by hydrolysis and purified (RNAeasy Minelute Kit; QIAGEN). cDNA
was synthesized with 5 mg random hexamers by Superscript III Reverse
Transcriptase (Invitrogen). Ds cDNA synthesis was performed according to the
manufacturer’s recommendations and purified (Minelute Reaction Cleanup Kit;
QIAGEN).
Sample preparation, cluster generation and sequencing (36 bp) was performed
with the Illumina Genome Analyzer IIx (GAIIx) platform according to standard
Illumina protocols. All sequencing results were mapped on the Mus musculus
NCBI m37 genome assembly (MM9; assembly July 2007). Normalized expression
values were obtained by Genomatix (http://www.genomatix.de). Functional
annotation analyses were performed using the Panther DB tool for biological
pathway (http://www.pantherdb.org), GO enrichment analysis was obtained using
DAVID (http://david.abcc.ncifcrf.gov). Raw data have been deposited on GEO:
GSE45909.
Protein analysis on 2D gels
Protein total extracts from TBV2 treated for 24 h with 0.5 mM MS-275, 5.0 mM
MS-275 or solvent were prepared. The mixture containing an equal aliquot of all
samples has been labelled with the fluorescent dyes Cy2, Cy3 and Cy5.
Experiments were performed as described previously (Cimmino et al., 2007).
Mass spectrometry and protein identification
Matched spots of interest were picked manually from the preparative gel. These
spots were subjected to in-gel trypsinization according to the manufacturer’s
protocol (Promega, USA). After overnight digestion, buffer containing the
peptides was recovered. Additional extraction of peptides was carried out with
100 ml of 50% acetonitrile in 1% formic acid. The extracts were poled and
vacuum-dried. For LC-MS/MS, peptide mixtures were dissolved in 50%
acetonitrile and 1% formic acid solution and analyzed with nano-LC system
(Applied Biosystems). Some spots were analyzed by off-line nano-spray method.
These peptides were dissolved in 20 ml of 50% acetonitrile in 0.1% formic acid.
Nano-spray ionization was carried out using an ion spray voltage of 900. The
spectra were acquired in an information dependent manner with Analyst QS 2.0
software to generate raw data. Database searching was completed using Mascot
search program (Version 1.6, Matrix Science, UK). Search parameters were as
follows: 1 missed cleavage allowed, carbamidomethylation set as fixed
modification, methionine oxidation as variable modification, peptide mass
tolerance 61.2 Da, fragment mass tolerance 60.6 Da, monoisotopic mass
values. Spectra were searched against NCBI or MSDB database. Criteria for
positive identification were a significant Mascot probability score (score .40;
p,0.05). Validated protein identification results are handed out in form of an
Excel file. Analysis of modulated proteins was performed with String software
(http://www.string-db.org).
Teratoma formation
For teratoma formation, 7–8-week-old Fox Chase SCID mice (Charles River,
Chatillon-sur-Chalaronne, France) were used. MS-275- or vehicle-treated ESCs
were resuspended in PBS (without Ca2+ and Mg2+) to a concentration of 1.56107
cells/ml. 36106 cells were injected subcutaneously in the flank of ten animals per
group. Tumor growth was monitored by three-weekly measurements of tumor
diameters with a caliper. Tumor volume (TV) was calculated according to the
following formula: TV (mm3)5d2*D/2, where d and D are the shortest and the
longest diameters, respectively. All the animals injected developed the tumor.
Mice were sacrificed when tumors reached the average volume of one cm3 in
controls, and 0.35 cm3, when MS-275 pretreated cells were used. Tumors were
paraformaldehyde-fixed and embedded in paraffin following standard procedures.
Five micrometer-thick deparaffined tumor sections were stained with
hematoxylin–eosin for the histological analysis. For immunohistochemistry, all
samples were processed with the standard streptavidin–biotin-immunoperoxidase
method (DAKO Universal Kit, DAKO Corp., Carpinteria, CA, USA). Monoclonal
antibody for Glial Fibrillary Acidic Protein (GFAP) (DAKO; Clone 6F2) and
polyclonal antibody Rabbit Anti-Cytokeratin (DAKO) were used at 1:100 dilution
for 1 hr. Diaminobenzidine was used as the final chromogen, and hematoxylin as
the nuclear counter stain. Negative control experiments for each tissue section
were performed in the absence of the primary antibody. Positive controls were
included in each experiment. The care and husbandry of mice and xenograft tumor
experimental procedures were in accordance with European Directives no. 86/609,
and with Italian D.L. 116. All the experiments have been approved by the Institute
of Genetics and Biophysics veterinarian.
Blastocyst injection
About 30 ESCs (vehicle or MS-275 in vitro pre-treated)/blastocyst were
microinjected, following standard procedures.
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Fig. S1. Effect of MS-275 on proliferation of ESC and validation panels for
HDAC activity in vitro and in cells. (A) Manual count of ESC treated with
MS-275 for 24 h compared with solvent and untreated cells. (B) In vitro assay
for HDAC1 inhibition upon the indicated treatments.
Fig. S2. Effect of epidrugs on histone modifications and HDACs expression
in ESC. (A) Western blot of the indicated targets upon the following
treatments: 1 (control), 2 (5.0 mM SAHA 24 h), 3 (0.5 mM SAHA 24 h), 4
(5.0 mM MS-275 24 h), 5 (0.5 mM MS-275 24 h), 6 (1.0 mM BIX-01294 24 h),
7 (0.1 mM BIX-01294 24 h); (B) heat map of semi-quantitation of histone
marks and HDACs upon the indicated treatments.
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Fig. S3. Stem cell potential impact of 0.5 mM MS-275 treatment on ESC.
(A) Experiment scheme; T: treatment 24 h 0.5 mM MS-275; p1–p4 days of
medium change and cell photo collection. (B) Western blot for H3K9
acetylation (Ac) after 24 h of MS-275 treatment at concentration of 0.5 mM and
acetylation levels at different passages (p1, p2, p3 and p4) after the same
treatment. (C) Photo in bright field of solvent and drug treatment at p1 and p4.
(D) Colonies formation assay for each day and treatment. Scale bars: 200 mm
(C), 400 mm (D).
Fig. S4. Difference in gel electrophoresis analysis
of MS-275 effect on ESC. (A) 2D-PAGE gels of
total protein extracts from ESC treated with MS-275
at 0.5 and 5.0 mM. For sample labeling see figure
scheme. (B) Venn diagrams displaying numbers of
up- and downregulated proteins (p-value of 0.009);
5.0 mM MS-275: downregulated 89 (86+3),
upregulated 107 (96+11) proteins; 0.5 mM MS-275:
downregulated 14 (11+3) and upregulated
27 (11+16).
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Fig. S5. Protein network of proteins identified in DIGE. Small red and green filled dots are representative of down- and upregulation, respectively. GO analysis of
Cluster was performed with string software.
Table S1. List of the modulators used in screening, with the respective final concentrations.
Drug name Concentration 1 Concentration 2 Concentration 3 Concentration 4
SAHA 5.0 mM 2.0 mM 1.0 mM 0.1 mM
VPA 10.0 mM 2.0 mM 1.0 mM 0.1 mM
Sodium butyrate 10.0 mM 1.0 mM 0.1 mM 0.01 mM
SK7068 5.0 mM 1.0 mM 0.5 mM 0.05 mM
Psammaplin A 5.0 mM 2.0 mM 1.0 mM 0.1 mM
MS-275 5.0 mM 2.0 mM 1.0 mM 0.1 mM
SB429201 5.0 mM 1.0 mM 0.5 mM 0.05 mM
Methylgene 5.0 mM 1.0 mM 0.5 mM 0.05 mM
SB379278 5.0 mM 1.0 mM 0.5 mM 0.05 mM
Sirtinol 100.0 mM 10.0 mM 1.0 mM 0.1 mM
EX527 500.0 nM 50.0 nM 1.0 nM 0.1 nM
BIX01294 10.0 mM 5.0 mM 1.0 mM 0.1 mM
ATRA 5.0 mM 1.0 mM 0.1 mM 0.01 mM
BMS641 10.0 mM 5.0 mM 1.0 mM 0.1 mM
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Table S2. Mass spectrometry-identified hits involved in neural differentiation processes upon MS-275 treatment.
SPOT Variation Identification Rules
536 30% HSP90AB1 Potential role of heat shock proteins in neural differentiation of murine embryonic
carcinoma stem cells
737 36% VCP Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the
quality control of endoplasmic reticulum in neuronal differentiated mammalian PC12
cells
904 52% MCM7 Accumulation and dynamics of proteins of the MCM family during mouse oogenesis and
the first embryonic cell cycle.
1028 27% HSPA5 Oocyte-targeted deletion reveals that hsp90b1 is needed for the completion of first
mitosis in mouse zygotes
1098 22% HSPA9 Nuclear GRP75 binds retinoic acid receptors to promote neuronal differentiation of
neuroblastoma
1448 55% DARS The signaling adapter protein DAP12 regulates multi-nucleation during osteoclast
development
1513 21% RUVBL1 Evolutionarily conserved transcriptional co-expression guiding embryonic stem cell
differentiation (WNT pathway)
1758 46% TUBA1A Regulated expression of transgenes in embryonic stem cell-derived neural cells
1950 33% NUDC NudC is required for interkinetic nuclear migration and neuronal migration during
neocortical development
2031 41% AHNAK2 Self-regulated alternative splicing at the AHNAK locus
Table S3. Statistical analysis of mouse embryo chimera formation.
Cells treated with vehicle were injected in the 30 blastocysts
Cells treated with 0.5 mM of Entinostat were injected in the 30 blastocysts
Cells treated with 5.0 mM of Entinostat were injected in the 19 blastocysts
Readout and analysis:
10 embryos pretreated in vitro with vehicle
10 embryos pretreated in vitro with 0.5 mM of Entinostat
9 embryos pretreated in vitro with 5.0 mM of Entinostat
EGFP evaluation:
8 out of 10 embryos (vehicle) showed broad EGFP signal
7 out of 10 embryos (0.5 mM MS-275) showed broad EGFP signal
All 9 embryos (5.0 mM MS-275) showed a clear absence of EGFP signal
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